肺切除术后新发持续阿片类药物使用的影响因素
本研究基于保险理赔数据,分析2010至2014年间接受肺切除的无阿片类药物暴露的癌症患者,发现14%的患者术后持续使用阿片类药物。多因素分析显示,年龄≤64岁、男性、术后住院时间、开胸手术及辅助治疗是独立危险因素。
要点
- 肺切除术后14%无阿片暴露患者出现新发持续阿片使用。
- 辅助治疗与开胸手术是持续阿片使用的最强危险因素。
- 需关注出院阿片处方管理及患者教育以降低持续使用风险。
核心结论
- 肺切除术后新发持续阿片使用率为14%,辅助治疗和开胸手术是最强危险因素。
研究设计与样本
- 回顾性队列研究,利用Truven Health MarketScan保险理赔数据库,纳入2010至2014年接受肺切除的无阿片暴露癌症患者3026例。
主要发现
- 患者平均年龄64±11岁,平均术后住院时间5.2±3.3天,6.5%接受新辅助治疗,21.7%接受辅助治疗。
- 多因素分析显示年龄≤64岁(OR 1.28,95%CI 1.03-1.59,p=0.028)、男性(OR 1.40,95%CI 1.13-1.73,p=0.002)、术后住院时间(OR 1.32,95%CI 1.05-1.65,p=0.016)、开胸手术(OR 1.58,95%CI 1.24-2.02,p<0.001)及辅助治疗(OR 2.19,95%CI 1.75-2.75,p<0.001)为独立危险因素。
临床怎么用
- 对年龄≤64岁、男性、开胸手术、较长住院时间及接受辅助治疗的患者,应加强阿片类药物管理。
- 关注减少过量处方、围手术期患者教育及安全处置阿片类药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioid dependence, misuse, and abuse in the United States continue to rise. Prior studies indicate an important risk factor for persistent opioid use includes elective surgical procedures, though the probability following thoracic procedures remains unknown. We analyzed the incidence and factors associated with new persistent opioid use after lung resection. METHODS: We evaluated data from opioid-naïve cancer patients undergoing lung resection between 2010 and 2014 using insurance claims from the Truven Health MarketScan Databases. New persistent opioid usage was defined as continued opioid prescription fills between 90 and 180 days following surgery. Variables with a p value less than 0.10 by univariate analysis were included in a multivariable logistic regression performed for risk adjustment. Multivariable results were each reported with odds ratio (OR) and confidence interval (CI). RESULTS: A total of 3,026 patients (44.8% men, 55.2% women) were identified as opioid-naïve undergoing lung resection. Mean age was 64 ± 11 years and mean postoperative length of stay was 5.2 ± 3.3 days. A total of 6.5% underwent neoadjuvant therapy, while 21.7% underwent adjuvant therapy. Among opioid-naïve patients, 14% continued to fill opioid prescriptions following lung resection. Multivariable analysis showed that age less than or equal to 64 years (OR, 1.28; 95% CI, 1.03 to 1.59; p = 0.028), male sex (OR, 1.40; 95% CI, 1.13 to 1.73; p = 0.002), postoperative length of stay (OR, 1.32; 95% CI, 1.05 to 1.65; p = 0.016), thoracotomy (OR, 1.58; 95% CI, 1.24 to 2.02; p < 0.001), and adjuvant therapy (OR, 2.19; 95% CI, 1.75 to 2.75; p < 0.001) were independent risk factors for persistent opioid usage. CONCLUSIONS: The greatest risk factors for persistent opioid use (14%) following lung resection were adjuvant therapy and thoracotomy. Future studies should focus on reducing excess prescribing, perioperative patient education, and safe opioid disposal.
引用
- Brescia AA, Harrington CA, Mazurek AA, et al. Factors Associated With New Persistent Opioid Usage After Lung Resection. Ann Thorac Surg. 2018. PMID: 30316852. doi:10.1016/j.athoracsur.2018.08.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。